Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study

Benefits and risks of interferon therapy for hepatitis B

(2010) Robert Perrillo   HEPATOLOGY

Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment

(2008) Henry Lik–Yuen Chan et al.   Clinical Gastroenterology and Hepatology

Predictive Factors for Early HBeAg Seroconversion in Acute Exacerbation of Patients With HBeAg-Positive Chronic Hepatitis B

(2008) Hyoung Su Kim et al.   GASTROENTEROLOGY

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

(2008) Rami Moucari et al.   HEPATOLOGY

Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B

(2008) Maurizia Rossana Brunetto et al.   HEPATOLOGY

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

(2008) Michael W. Fried et al.   HEPATOLOGY

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

(2008)   JOURNAL OF HEPATOLOGY

Hepatitis B Virus Infection

(2008) Jules L. Dienstag   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: A meta-analysis

(2007) Yong-Feng Yang et al.   ANTIVIRAL RESEARCH